Related Experiment Videos
Impact of statins on novel risk markers
Andrea Cignarella1, Chiara Bolego, Rodolfo Paoletti
1Department of Pharmacological Sciences, University of Milan, Italy.
Insights
Statins significantly reduce cardiovascular and cerebrovascular events by improving lipid profiles and affecting inflammatory and morphologic markers. These drugs offer a broad clinical benefit beyond cholesterol reduction, impacting overall risk.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Long-term trials show 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) reduce cardiovascular and cerebrovascular events.
- Statins benefit patients with and without pre-existing heart disease.
Purpose of the Study:
- To review the pleiotropic effects of statins beyond lipid profile improvement.
- To highlight how statins affect novel and established risk markers.
Main Methods:
- Review of long- and short-term clinical trials on statin efficacy.
- Analysis of statin's impact on lipid, inflammatory, and morphologic markers.
Main Results:
- Statins significantly reduce cardiovascular and cerebrovascular events.
- Statin treatment improves lipid profiles and affects markers like LDL subclasses, lipoprotein (a), endothelial function, inflammatory mediators, intima-media thickening, and coronary calcification.
- Some statins possess unique properties beneficial for specific risk factors.
Conclusions:
- Statins offer substantial clinical benefits through lipid modification and pleiotropic effects.
- Statin therapy contributes to a reduced global risk profile by targeting multiple cardiovascular risk factors.
Abstract:
Long-and-short term trials with the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have demonstrated significant reductions in cardiovascular and cerebrovascular events in patients with and without preexisting heart disease. Beyond improving the lipid profile, statins have additional effects that may contribute to their overall clinical benefit. Statin treatment appears to reduce global risk profile by affecting both novel and established lipid, inflammatory, and morphologic markers including low-density lipoprotein subclasses, lipoprotein (a), markers of endothelial function, inflammatory mediators, intima-media thickening, and coronary calcification. Although statins may be regarded as a rather homogeneous drug class in terms of biological activity, some agents feature unique properties that have beneficial effects on selected important risk matters.